Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/6/2008

illion and $37.4 million for the corresponding periods in 2006. The 2007 increase primarily resulted from higher sales and marketing expenses associated with the expansion of ISTA's sales force in early 2007. Stock-based compensation expenses included in SG&A for the fourth quarter and for the year ended December 31, 2007 were $0.8 million and $2.5 million, respectively.

The net loss for the fourth quarter and year ended December 31, 2007, was $9.9 million (or $0.30 per share) and $38.2 million (or $1.29 per share), respectively, compared with a net loss of $6.4 million (or $0.25 per share) and $38.4 million (or $1.48 per share) for the same periods in 2006. At December 31, 2007, ISTA had cash and short-term investments of $46.1 million.

2007 Corporate Highlights

-- Increased net revenue by 56% and 78% as compared to the fourth quarter

of 2006, and year ended December 31, 2006, respectively

-- Filed an NDA with the FDA for Xibrom QD (once-daily) in December of

2007 after announcing, earlier in the year, positive Phase III results

for Xibrom QD as a treatment for inflammation, pain, and photophobia

following cataract surgery

-- Announced statistically significant Phase II/III study results for

Bepreve in treating ocular itching and clinical improvement in redness

and initiated both the Bepreve ocular safety study and the second

Phase III study

-- Announced positive results from the ecabet sodium Phase IIb study for

the treatment of dry eye syndrome

-- Successfully completed $36.7 million financing through the private

placement of 5.25 million shares of common stock with institutional

accredited investors at a purchase price of $7.00 per share

-- Expanded pipeline in allergy treatments by licensing exclusive North

American rights to nasal dosage forms of bepotastine, an

investigation
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
2. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
3. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
7. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
8. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
9. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
10. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
11. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... SPRINGS, Florida , September 19, 2014 ... companies release latest developments, patents and results of studies ... GNSZ), Eli Lilly and Company (NYSE: LLY ... Celgene Corporation (NASDAQ: CELG ) and Arena ... GNSZ), a leader in developing prodrug therapeutics for the ...
(Date:9/19/2014)... 2014 , The first grants ... Paediatric Endocrinology (ESPE) Meeting  Investment supports innovative ... in the field of growth  , EMD ... Germany , today announced the first recipients of ... awards were announced during a Satellite Symposium organized by ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... DUBLIN, Ireland , September 18, ... ,Research and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) ... "Biocompatible Materials - Global Strategic ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report ... Materials in US$ Million by the ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... , , CLEVELAND, Sept. 9 ... for ways to drive out costs and inefficiencies. Because it,s proven ... documents that go along with them, many are turning to enterprise ... the roadblock: budgets are tighter than ever, so how do these ...
... , , THE WOODLANDS, Texas, Sept. ... LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments ... Ph.D. , Lexicon,s president and chief executive officer, will present at ... in New York, New York on Tuesday, September 15, 2009 at 1:35 ...
... BRIDGEWATER, England, September 9 Clinical Therapeutics,(, http://www.clinicaltherapeutics.com/ ... announce the addition of Michael G. Spigarelli, MD, ... As section editor for the Pediatric, ... the,Pediatric Research section), Dr. Spigarelli brings a wealth ...
Cached Biology Technology:Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 2Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 3Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 4Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section 2
(Date:9/19/2014)... species which over thousands of years has adapted to the ... that makes the cold dangerous for you. , This is ... and the cold provoking substance, called nonylphenol, comes from the ... suspected of being a endocrine disruptor, but when entering the ... ability to protect the cells in its body from cold ...
(Date:9/18/2014)... Boulder, Colo., USA A new GSA Bulletin ... along the lower Rio Puerco and Chaco Wash in ... tree rings from salt cedar and willow, investigators were ... thick or greater. They then combined this data with ... reconstruct the history of these arroyos. , Arroyos are ...
(Date:9/18/2014)... A novel robotic system that can operate inside the ... as part of a biomedical research partnership program at ... of determining if the robot, in conjunction with real-time ... accurate, less costly, and less discomforting for the patient. ... prostate cancer therapies with greater precision. , Developed by ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
... the Sundarbans, resulting in as much as 200m of coast ... (11th Jan) in Remote Sensing by scientists from ... development thrives, and global temperature continues to rise, natural protection ... rates. This will inevitably lead to species loss in this ...
... W. Finberg, MD, the Richard M. Haidack Professor of ... University of Massachusetts Medical School, is lead investigator on ... predicting how the influenza virus changes and evolves in ... This approach has promise for becoming a pivotal tool ...
... cells can be grown on biocompatible scaffolds to form ... repair and regeneration of damaged or diseased tissue. However, ... a specific pattern or alignment. An innovative method for ... tissue architectures is described in an article in ...
Cached Biology News:Bengali forests are fading away 2
...
Human Presenilin-2 NTF Affinity Purified Polyclonal Ab...
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
Human Glypican 2 Biotinylated Affinity Purified PAb...
Biology Products: